Diabetes Mellitus, Non-Insulin-Dependent | C-Peptide Positive | Insulin C-peptide measurement
Item
type 2 dm study participants will be c-peptide positive (levels > 0.3 nmol/l)
boolean
C0011860 (UMLS CUI [1])
C0006558 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0202100 (UMLS CUI [3])
Insulin | Metformin | Sulfonylurea | Meglitinide
Item
receiving insulin, metformin and/or sulfonylurea/glitinide.
boolean
C0021641 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C0065880 (UMLS CUI [4])
Antihypertensive Agents Stable
Item
maintained on stable anti-hypertensive medication.
boolean
C0003364 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
Body mass index
Item
bmi < 52 kg/m2.
boolean
C1305855 (UMLS CUI [1])
Non-Insulin-Dependent Diabetes Mellitus Disease length | Hemoglobin A1c measurement
Item
t2dm for at least 3 months with hba1c under 10%.
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0474680 (UMLS CUI [2])
Thiazolidinediones | exenatide | sitagliptin | Pramlintide
Item
receiving tzds, exenatide, sitagliptin or pramlintide therapy.
boolean
C1257987 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C1565750 (UMLS CUI [3])
C0537551 (UMLS CUI [4])
Pharmaceutical Preparations Impairing Gastric Emptying | Pharmaceutical Preparations Impairing Intestinal Motility | Pharmaceutical Preparations Impairing Glucagon secretion | Adrenal Cortex Hormones
Item
receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
boolean
C0013227 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0017127 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
C0021838 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C0221099 (UMLS CUI [3,2])
C2610739 (UMLS CUI [3,3])
C0001617 (UMLS CUI [4])
Triglycerides measurement
Item
triglyceride levels > 400 mg/dl.
boolean
C0202236 (UMLS CUI [1])
Body mass index
Item
bmi > 52 kg/m2.
boolean
C1305855 (UMLS CUI [1])